Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Safranal** is a naturally occurring monoterpene aldehyde (C10H14O), primarily responsible for the distinctive aroma of saffron, obtained from the flowers of the Crocus sativus plant. It forms via enzymatic and thermal degradation of picrocrocin during saffron drying and storage[1][3][5]. Safranal acts mainly as an agonist at the gamma aminobutyric acid type A (GABAA) receptor-benzodiazepine complex, conferring anticonvulsant and central nervous system effects[5][11]. It also possesses antioxidant, cytotoxic (anticancer), and antidepressant activities, and has demonstrated antihyperglycemic and potential neuroprotective effects in preclinical studies[1][5][10][11]. Safranal is not currently a pharmaceutical product but is studied as a bioactive dietary constituent and aromatic agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on safranal.